Growth Factor Inhibitors This class of agents includes Vascular Endothelial Growth Factor (VEGF) inhibitors that inhibit tumour angiogenesis such as bevacizumab and pazopanib, the latter of which also inhibits platelet derived growth factor (PDGF). This evidence concerns the gene VEGFA and neoplasm.